Glucagon-Like Peptide 1 Receptor Agonists-Pipeline Insight, 2021 | Analytical Research Cognizance

Glucagon-Like Peptide 1 Receptor Agonists-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667923
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 100
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Glucagon-Like Peptide 1 Receptor Agonists Understanding
Glucagon-Like Peptide 1 Receptor Agonists: Overview
The human Glucagon-Like Peptide 1 Receptor (GLP-1) receptor is located on chromosome 6 (6p21). The GLP-1 receptor sequence contains a large hydrophilic extracellular domain and seven hydrophobic transmembrane domains. Glucagon-like peptide-1 amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple physiological effects make it an attractive candidate for type 2 diabetes therapy. Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Glucagon-Like Peptide 1 Receptor Agonists R&D. The therapies under development are focused on novel approaches for Glucagon-Like Peptide 1 Receptor Agonists.

Glucagon-Like Peptide 1 Receptor Agonists Emerging Drugs Chapters
This segment of the Glucagon-Like Peptide 1 Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucagon-Like Peptide 1 Receptor Agonists Emerging Drugs
IBI-362: Innovent Biologics
IBI362 is a long-acting synthetic peptide related to mammalian oxyntomodulin (OXM). Similar to OXM, IBI362 binds to and activates both the glucagon-like peptide -1 receptor (GLP-1R) and the glucagon receptor (GCGR). IBI362 uses a fatty acid side chain to prolong the duration of action and allow once-weekly administration. Innovent entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 in China (IBI362), and Lilly is developing it outside China. IBI-362 has the potential to be developed as an important therapy for diabetes, obesity and potentially nonalcoholic steatohepatitis (NASH), and may provide a more effective treatment regimen for overweight and obese patients.

Tirzepatide: Eli Lilly and Company
Tirzepatide is a once-weekly acylated, long-acting dual glucose-dependent insulinotropic peptide (GIP) and a glucagon-like-peptide 1 (GLP-1) receptor agonist. It integrates the actions of both incretins into a single novel molecule. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase III development for blood glucose management in adults with type 2 diabetes and for chronic weight management. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH).
Further product details are provided in the report……..

Glucagon-Like Peptide 1 Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Glucagon-Like Peptide 1 Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Glucagon-Like Peptide 1 Receptor Agonists
There are approx. 30+ key companies which are developing the Glucagon-Like Peptide 1 Receptor Agonists. The companies which have their Glucagon-Like Peptide 1 Receptor Agonists drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Glucagon-Like Peptide 1 Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glucagon-Like Peptide 1 Receptor Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide 1 Receptor Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide 1 Receptor Agonists drugs.

Glucagon-Like Peptide 1 Receptor Agonists Report Insights
Glucagon-Like Peptide 1 Receptor Agonists Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Glucagon-Like Peptide 1 Receptor Agonists Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing Glucagon-Like Peptide 1 Receptor Agonists drugs?
How many Glucagon-Like Peptide 1 Receptor Agonists drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for Glucagon-Like Peptide 1 Receptor Agonists?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucagon-Like Peptide 1 Receptor Agonists therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Glucagon-Like Peptide 1 Receptor Agonists and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Eli Lilly and Company
Innovent Biologics
Novo Nordisk
AstraZeneca
Biolingus
D and D Pharmatech
Terns Pharmaceuticals
i2O Therapeutics

Key Products
Tirzepatide
IBI-362
Semaglutide subcutaneous
Exenatide
Liraglutide biobetter
Exenatide/insulin sublingual
DD-02
GLP-1R agonist therapeutic
GLP1 analogs

Introduction
Executive Summary
Glucagon-Like Peptide 1 Receptor Agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glucagon-Like Peptide 1 Receptor Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glucagon-Like Peptide 1 Receptor Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucagon-Like Peptide 1 Receptor Agonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IBI-362: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Exenatide/insulin sublingual: Biolingus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Glucagon-Like Peptide 1 Receptor Agonists Key Products
Glucagon-Like Peptide 1 Receptor Agonists- Unmet Needs
Glucagon-Like Peptide 1 Receptor Agonists- Market Drivers and Barriers
Glucagon-Like Peptide 1 Receptor Agonists- Future Perspectives and Conclusion
Glucagon-Like Peptide 1 Receptor Agonists Analyst Views
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Appendix

Table 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products